Clinuvel Pharmaceuticals Ltd (ASX: CUV) shares are pushing higher on Monday.
At the time of writing, the ASX 300 stock is up 6.5% to $13.48.
What's going on with this ASX 300 stock?
Investors have been buying the biotechnology company's shares after it unveiled encouraging progress on a brand new drug delivery platform that could materially expand its long-term growth runway.
According to the release, Clinuvel has commenced dosing in a preclinical study of its controlled-release liquid injectable peptide platform, known as VLRX-L.
This marks the first time one of the ASX 300 stock's next-generation delivery technologies has entered formal preclinical evaluation. This is a milestone that investors have clearly welcomed judging by its share price move on Monday.
What is VLRX-L?
The announcement reveals that VLRX-L has been designed to control the release of peptides, including Clinuvel's melanocortin-based drugs, through a flexible liquid dose.
The current preclinical study is focused on assessing safety, release kinetics, and the reproducibility of drug delivery using in-vitro models. Results from the study are expected in the second half of 2026.
Importantly, this platform has been developed entirely in-house at Clinuvel's Research, Development & Innovation Centre in Singapore. The VLRX-L program follows more than a decade of research into peptides, polymers, and controlled-release delivery systems. Management believes this highlights the depth of capability that the company has quietly been building behind the scenes.
The company's Chief Scientific Officer, Dr Dennis Wright, described the early in-vitro data as encouraging and reproducible. He said:
Through extensive preliminary work and iterative innovation we have arrived at a VLRX-L candidate platform that has demonstrated encouraging, reproduceable results in-vitro. The platform now needs to be challenged in in-vivo models to understand how it may ultimately deliver therapies for patients.
If these initial results are successful in 2026, we will look at the optimal pathways to scale up and commercialise this technology, with a view to extensively expanding our pipeline with our own IP.
Speaking about the ASX 300 stock's long term goal, Dr Wright said:
Long-term, the goal is to establish a suite of delivery platforms for melanocortins, and other peptides, which meet the diverse needs of a range of patient groups, addressing some of the challenges of technologies currently offered on the market. It is exciting that we can now start to unveil the work of our VALLAURIX team and our ambitions for the next generation of CLINUVEL's products.
Clinuvel Pharmaceuticals shares are now up almost 20% since this time last year.
